Lv1
100 积分 2022-04-11 加入
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
2个月前
已完结
FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
7个月前
已完结
Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy
7个月前
已完结
Species Differences in Pharmacokinetics and Pharmacodynamics
9个月前
已完结
PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma
9个月前
已完结
Comparison of tucidinostat with CHOP-like versus CHOP-like in first-line treatment of peripheral T-cell lymphoma: a single-center real-world study
10个月前
已完结
Targeting S-adenosylmethionine biosynthesis with a novel allosteric inhibitor of Mat2A
11个月前
已完结
Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers
1年前
已完结
Dosage-effect of selenium supplementation on blood glucose and oxidative stress in type 2 diabetes mellitus and normal mice
1年前
已完结
Abstract 3319: The MTA-cooperative PRMT5 inhibitor, MRTX1719, demonstrates increased anti-tumor activity in combination with KRAS mutant-selective inhibitors in MTAP del,KRAS-mutant cancers
1年前
已关闭
皖公网安备34019202002308
